Clinical Trial Update: Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Restoring Cognitive Control (ReCon) in acute nicotine withdrawal has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impulse Control Disorder

Drugs mentioned

• Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal

Snippet

Sponsor: Promentis Pharmaceuticals, Inc. | Conditions: Impulse Control Disorders | Phase 2 | Status: COMPLETED | Results posted: 2020-07-17